Natco Pharma Ltd. Share Price

Natco Pharma Launches Cancer Drug in US Market

has announced the launch of Carboplatin Injection, a generic version of Paraplatin, in the US market through its subsidiary Natco Pharma USA LLC. The product is manufactured in collaboration with Chennai-based Teyro Labs Pvt Ltd. Carboplatin Injection is used in the treatment of advanced ovarian cancer, including first-line combination therapy and treatment of recurrent disease. The launch comes amid a critical shortage of the drug in the US, creating an opportunity for Natco to address existing demand. According to industry sales data, Carboplatin Injection recorded approximately $27.8 million in US sales during the 12 months ended June 2026. This represents the overall product market size, not Natco's expected revenue. From a research perspective, the launch strengthens Natco's oncology portfolio and its presence in the US generics market. The company already has an established international pharmaceutical business, with US revenue of approximately ₹2,381 crore in FY26. The ongoing drug shortage could support initial demand. However, the financial contribution will depend on market share, product pricing, manufacturing capacity and competition from existing suppliers. Investors should monitor US sales traction, product margins, supply availability and future oncology launches. Generic drug prices can face pressure as competition increases, even when initial demand is strong. Learning Takeaway: A pharmaceutical product launch creates a revenue opportunity, but market size does not equal company revenue. Investors should evaluate market share, competition, pricing and profitability before estimating its earnings impact. Disclosure: This post is for educational purposes only and does not constitute investment advice. Any holdings or conflicts of interest should be disclosed separately.

See More

Natco ₹1,279 Cr Rights Issue to Strengthen Balance Sheet

has approved a ₹1,279.36 crore rights issue, marking a significant capital-raising exercise for the pharmaceutical company. The issue will involve the issuance of 1.71 crore equity shares at ₹750 per share, with the proceeds providing additional financial flexibility for the company. The company will issue 1,70,58,082 new shares at ₹750 each, including a face value of ₹2 and a premium of ₹748 per share. If fully subscribed, the new shares would increase Natco Pharma's equity base by approximately 9.5%. The rights issue is structured as 2 new shares for every 21 shares held, with October 1, 2026 fixed as the record date. The issue is scheduled to open on October 12 and close on October 22, 2026. For existing shareholders, the rights structure allows them to maintain their proportional ownership by subscribing to their entitlement.

See More

Natco Pharma board approves rights issue to raise funds

Natco Pharma board approves rights issue to raise up to ₹1,279 crore SEBI RA – Shubh Consultancy – Sunil Kotak – INH000015826

Drug maker Natco Pharma on Friday said its board of directors has approved the issuance of equity shares through a rights issue to raise up to ₹1,279.35 crore. According to a regulatory filing, the company will issue up to 1,70,58,082 equity shares of face value of ₹2 each at an issue price of ₹750 per share to raise an amount not exceeding ₹1,279.35 crore. The rights issue has been approved at the entitlement ratio of 2 rights equity shares for every 21 fully paid-up equity shares held by eligible shareholders as on the record date, which has been fixed as October 1, 2026. The rights issue is scheduled to open on October 12, 2026, and close on October 22, 2026. The on-market renunciation period will run from October 12 to October 16, 2026. Upon full subscription, the company's outstanding equity shares will rise from 17,91,09,870 shares to 19,61,67,952 shares post-issue. The board also approved amendments to the company's code of conduct to regulate, monitor, and report trading by designated persons during its meeting held on Friday, the filing added. All this is for information This is not a buy/sell recommendation. Thank you, Technofunda24

See More

Natco Pharma's Slide Continues Even as Its Sector Rallies

has been quietly bleeding for months, and today's close tells a mixed story. The stock settled at ₹818.25, actually up slightly from its previous close of ₹813.29, a modest gain of around 0.6%, but still well short of keeping pace with the broader Nifty Pharma index, which jumped 1.66% and snapped a five-session losing streak. So while Natco didn't fall today, it still lagged its own sector by a wide margin. The stock remains in a well-established downtrend. It's down roughly 10% over the past month and nearly 15% over six months, still trading much closer to its 52-week low of ₹789 than its high of ₹1,226.80. A rights issue and demerger are weighing on sentiment. On September 9, the board approved a ₹1,300 crore rights issue alongside an updated demerger plan, this kind of corporate action typically keeps investors on the sidelines until dilution and structure become clearer. Technicals had been signaling oversold conditions. As of mid-September, RSI was near 29 with a negative MACD, so today's modest bounce could be an early sign of that oversold pressure easing, though one day isn't enough to call a reversal. There's a longer-term growth angle too. The company invested $14 million in US biotech firm eGenesis in late August, showing it's still funding future pipeline bets even through the price weakness.

See More

NATCO PHARMA PROPOSES ₹1,300 CR RIGHTS ISSUE

NATCO PHARMA PROPOSES ₹1,300 CR RIGHTS ISSUE

NATCO Pharma has proposed a rights issue of equity shares with a face value of ₹2 each. The issue price is yet to be determined. The proposed rights issue will aggregate up to ₹1,300 crore, with the funds planned to be utilised for prepayment of borrowings, research and development initiatives, and inorganic growth opportunities. The fundraising is aimed at strengthening the company’s balance sheet while providing additional capital to support future expansion and strategic investments. The final issue price, number of shares and other key terms of the rights issue are yet to be announced. Impact: Positive — The proposed ₹1,300 crore fundraise could strengthen NATCO Pharma’s balance sheet through debt repayment while providing funds for R&D and inorganic growth. However, the impact on existing shareholders will also depend on the final issue price and extent of dilution.

See More

Natco Pharma’s Next Act: Beyond Generics

, traditionally known for its strong generics portfolio, is now diversifying into innovative therapies. CEO Rajeev Nannapaneni emphasized that while generics remain core, the company is actively investing in specialty drugs and new therapeutic areas to sustain long‑term growth. Focus on GLP‑1 Segment: The company is targeting semaglutide, a GLP‑1 receptor agonist used in diabetes and obesity treatment. With global demand surging, Natco aims to develop cost‑effective alternatives, positioning itself as a competitive player in this high‑growth segment. Pipeline Expansion: Natco is building a robust pipeline of niche products, including oncology and chronic disease therapies. The strategy is to identify areas with unmet medical needs and limited competition, thereby creating strong entry barriers and higher margins compared to traditional generics. Financial Discipline: Despite the push into new areas, Natco remains cautious about capital allocation. The company is balancing R&D investments with profitability, ensuring that expansion into specialty drugs does not compromise financial stability. Global Market Ambitions: Natco is eyeing international markets, particularly the U.S., for its upcoming launches. By leveraging partnerships and regulatory expertise, the company hopes to replicate its domestic success abroad, especially in segments where affordability is a key differentiator. Leadership Vision: Nannapaneni’s approach reflects a blend of pragmatism and ambition—retaining generics as a steady revenue base while gradually scaling up specialty and innovative products. This dual strategy is designed to future‑proof Natco against pricing pressures and intensifying competition in generics.

See More